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Abstract
Background: Apolipoprotein E polymorphisms (APOE) have been associated with lowered glomerular
filtration rate (GFR) and chronic kidney disease (CKD) with e2 allele conferring risk and e4 providing
protection. However, few data are available in non-European ethnic groups or in a population-based
cohort.
Methods:  The authors analyzed 5,583 individuals from the Third National Health and Nutrition
Examination Survey (NHANES III) to determine association with estimated GFR by the Modification of
Diet in Renal Disease (MDRD) equation and low-GFR cases. Low-GFR cases were defined as GFR <75 ml/
min/1.73 m2; additionally, GFR was analyzed continuously.
Results: In univariate analysis, the e4 allele was negatively associated with low-GFR cases in non-Hispanic
whites, odds ratio (OR): 0.76, 95% confidence interval (CI): 0.60, 0.97. In whites, there was a significant
association between increasing APOE score (indicating greater number of e2 alleles) and higher prevalence
of low-GFR cases (OR: 1.21, 95%CI: 1.01, 1.45). Analysis of continuous GFR in whites found the e4 allele
was associated with higher levels of continuous GFR (-coefficient: 2.57 ml/min/1.73 m2, 95%CI: 0.005,
5.14); in non-Hispanic blacks the e2 allele was associated with lower levels of continuous GFR (-
coefficient: -3.73 ml/min/1.73 m2, 95%CI: -6.61, -0.84). APOE e2 and e4 alleles were rare and not associated
with low-GFR cases or continuous GFR in Mexican Americans.
Conclusion: In conclusion, the authors observed a weak association between the APOE e4 allele and low-
GFR cases and continuous GFR in non-Hispanic whites, and the APOE e2 allele and continuous GFR in non-
Hispanic blacks, but found no association with either measure of kidney function in Mexican Americans.
Larger studies including multiethnic groups are needed to determine the significance of this association.
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Background
Chronic kidney disease (CKD) is a major public health
issue in the United States; CKD prevalence is estimated to
be between 4.8% and 7.0% in U.S. adults, with higher
prevalence observed in US non-Hispanic whites (7.5%)
and non-Hispanic blacks (7.8%) and lower prevalence in
Mexican Americans (1.8%) [1]. The discrepancy in preva-
lence of disease by ethnicity may be due to differences in
access to healthcare, prevalence of modifiable lifestyle risk
factors for CKD, or in genetic risk factors [2,3]. Kidney
function can be estimated by the continuous glomerular
filtration rate (GFR) using various equations, including
the Modification of Diet in Renal Disease (MDRD) equa-
tion [4,5]. Individuals with low GFR are considered to
have CKD, which is commonly defined by a GFR <60 ml/
min/1.73 m2 using the MDRD equation [1,6].
Both continuous GFR and CKD are heritable [7,8] and
previous studies, including our own work, suggest APOE
genetic variations may contribute to risk of CKD and low
GFR. APOE polymorphisms have been the focus of several
studies investigating lipid transport in the kidney [9-23].
The ability of ApoE to bind and clear lipids in the kidney
is directly related to structural instability and repair of the
glomerular lining of the kidney [11,24,25]. ApoE glyco-
protein forms are coded by three APOE alleles, e2, e3 and
e4 [26,27]. The e3 form is the most common and is not
associated with increased risk of CKD. e4 has been associ-
ated with higher GFR and decreased risk of CKD [28] but
increases risk of Alzheimer's disease [29,30] and coronary
artery disease [31]. On the other hand, e2, the rarest ApoE
isoform [28,32] has been shown to be associated with
increased risk of CKD and lower GFR although it affords
protection against Alzheimer's disease [33,34] and lowers
cholesterol levels [35].
We previously demonstrated an association between
APOE polymorphisms and incident CKD in the Athero-
sclerosis Risk in Communities (ARIC) study, a large com-
munity based prospective study of middle-aged white and
African-American adults [28]. In the present study, we fur-
ther investigate the association between APOE polymor-
phisms and low-GFR cases in a large nationally
representative population-based sample of non-Hispanic
Whites, non-Hispanic blacks and Mexican Americans
from the Third National Health and Nutrition Examina-
tion Survey (NHANES III). The goals of this study are to
1) obtain population-based estimates of APOE allele and
genotype frequencies across a wide range of age groups
and by three ethnicities in the US; 2) determine the asso-
ciations between APOE  polymorphisms and low-GFR
cases by ethnicity; and 3) determine whether allele fre-
quencies can account for part of the differences in preva-
lence of low-GFR cases between populations.
Methods
Study population
Data from a subset of NHANES III participants who con-
sented to genetic research and were successfully geno-
typed were used in the present analysis (n = 7,159). The
NHANES III examinations were carried out from 1988 to
1994 by the National Center for Health Statistics using a
complex multistage probability sampling design [36,37].
Sample weights were applied to the population to correct
for non-response and unequal probability of selection.
DNA was obtained by growing cell lines from blood sam-
ples collected from consenting participants over the age of
12 during the second phase of NHANES III from 1991 to
1994. To avoid non-response bias, original sample
weights were recalculated for the genetic subset [38,39].
Informed consent has been obtained from patients when
appropriate. Procedures were followed in accordance with
ethical standards of the Johns Hopkins School of Public
Health Office of Human Subjects Research and Institu-
tional Review Board.
Exclusions
The following exclusion criteria were applied to derive the
final analytical sample size of 5,583: missing genotypes (n
= 80), self-reported "other" ethnicity due to small sample
size (n = 333), missing serum creatinine measurement (n
= 31), or younger than 20 years (n = 1,119). After exclu-
sion, the total number of subjects available for analysis
was 5,583 (2,328 non-Hispanic whites, 1,599 non-His-
panic blacks and 1,656 Mexican Americans).
Outcome - Glomerular Filtration Rate
Serum creatinine (SCr) measures using modified kinetic
Jaffe reaction were calibrated to standardized creatinine
reference methods by multiplying by 0.960 and then sub-
tracting 0.184 mg/dl from the recorded values [40]. The
MDRD equation was used to estimate GFR [41]:
In addition to the MDRD equation, the newly developed
CKD-EPI formula [see Additional file 1] was also used to
estimate GFR[42]. GFR values >200 ml/min/1.73 m2 were
set to have the maximum value of 200 ml/min/1.73 m2
[1].
Given the low count of CKD cases (as defined by GFR <60
ml/min/1.73 m2) in the smaller NHANES III Genetics
Study and the low frequency of the APOE e2 allele, we
defined low-GFR cases as individuals having GFR <75 ml/
min/1.73 m2 and controls having GFR  75 ml/min/1.73
m2 [43].
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APOE genotyping
The APOE polymorphism consists of two single nucle-
otide polymorphisms (SNPs), APOE  Cys112Arg
(rs429358; T to C nucleotide substitution) and APOE
Arg158Cys (rs7412; C to T nucleotide substitution). The
native APOE e3 allele consists of Cys112 and Arg158; the
e2 allele is a combination of Cys112 and 158Cys; and the
e4 allele is a combination of 112Arg and Arg158. Geno-
typing of the two SNPs was performed using the TaqMan
assay as previously described [28]. Percent agreement for
440 replicates was 100%. Both SNPs were in Hardy-Wein-
berg proportion.
Covariates
Demographic and health status information were col-
lected during detailed home interviews and extensive
physical exams at Mobile Examination Centers (MEC) or
in home examinations and have been described in detail
[36]. Age, sex and ethnicity were self reported, with eth-
nicity selected from non-Hispanic white, non-Hispanic
black, Mexican-American or other. Variables included in
analysis obtained during the interview include: smoking
(ever/never smoked) and educational status (less than
high school degree/at least high school degree). Body
mass index (BMI) was defined by height and weight meas-
ured at the exam. Blood samples were collected by veni-
puncture for measurement of serum creatinine (SCr),
blood glucose, total serum cholesterol, high density lipo-
protein (HDL) cholesterol, thyroid stimulating hormone
(TSH), triglycerides and C-reactive protein (CRP) accord-
ing to NHANES III lab protocols [44,45].
Diabetes status was established by self-report of diabetes,
self-report of diabetes medication, fasting plasma glucose
 7.0 mmol/l (126 mg/dl), or a 2-hr glucose level  11.1
mmol/l (200 mg/dl) after a 75-g oral glucose tolerance
test. Systolic and diastolic blood pressures were deter-
mined by the average of 3 blood pressure measurements
taken during the examination. Participants were classified
as hypertensive by self-report of hypertension, report of
anti-hypertensive medication, systolic blood pressure 
140 mmHg or diastolic blood pressure  90 mmHg. High
blood cholesterol was defined by self-reported high blood
cholesterol, report of lipid-lowering medications or total
serum cholesterol  6.2 mmol/l ( 240 mg/dl). Obesity
was defined by BMI  30 kg/m2. Prevalent cardiovascular
disease was ascertained by self-report of coronary heart
disease, myocardial infarction, or stroke. Urine albumin
was measured using a solid-phase fluorescent immu-
noassay and urine creatinine was measured using the Jaffe
rate reaction [45]; the urinary albumin-creatinine ratio
(ACR) was calculated as ug/mg. Albuminuria was defined
as ACR>30 ug/mg by the National Kidney Foundation.
Statistical analysis
Analyses were weighted to account for the sampling
design of NHANES III; recalculated weights from
NHANES III were applied to NHANES III Genetic Study.
The "survey" command in Stata 10.0 was used for all anal-
yses [46]. Analyses were stratified by self-reported ethnic-
ity. Allele frequencies and genotype distributions were
calculated with and without sampling weights; the two
sets of results had minimal differences.
All alleles were modeled additively. Prior research indi-
cated the e2 allele as the at-risk allele for low-GFR/CKD,
e4 as the protective allele, and e3 as the reference. A sum-
mary score was used to model APOE variation by desig-
nating each e2, e3 and e4 allele +1, 0 and -1 points,
respectively [28]. Using this model, +2 points were
assigned to individuals of genotype e2/e2, +1 point for e2/
e3, 0 points for e3/e3 and e2/e4, -1 points for e3/e4 and -
2 points for e4/e4 individuals [28].
The association between low-GFR cases and APOE poly-
morphism was assessed using logistic regression. Models
estimating allele-specific odds ratios are adjusted for the
e2 and the e4 allele simultaneously. The minimally
adjusted model includes age and sex. Covariate selection
was based on a priori hypotheses of risk factors and
comorbidities; the final fully adjusted model included
age, sex, education, ever/never smoking, CRP, triglycer-
ides, HDL cholesterol, TSH, diabetes, hypertension and
obesity. In addition, we wanted to explore the pathway
between APOE and low-GFR independent of albuminuria
(ACR > 30 ug/mg, as defined by the National Kidney
Foundation), representing evidence of physical kidney
damage. We performed an analysis using the univariate
model adjusted for presence of albuminuria and added
presence or absence of albuminuria to our final model.
Analysis of the association between APOE  polymor-
phisms and continuous GFR was assessed using linear
regression.
Power calculations were carried out using Quanto [47]
and POWER V3.0 [48].
Results
Population characteristics
A summary of characteristics, by ethnicity and case-con-
trol status, of the 5,583 NHANES III participants included
in the present study are presented in table 1. Non-His-
panic white participants had a mean age of 46.2 years, had
the lowest BMI and were more likely to have dyslipidemia
but less likely to have diabetes. The mean age of the non-
Hispanic black participants was 41.8 years, and they had
the highest prevalence of diabetes, hypertension, cardio-
vascular disease, and obesity. The mean age of the Mexi-
can Americans was only 37.4 years, which probablyBMC Medical Genetics 2009, 10:108 http://www.biomedcentral.com/1471-2350/10/108
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accounted for the observation that they tended to have
lower prevalence of existing cardiovascular risk factors
shown in table 1.
Prevalence of low-GFR (<75 ml/min/1.73 m2) by the
MDRD equation was the lowest in Mexican Americans
(6.4%, estimated from 174 cases) compared to either
non-Hispanic whites (22.8%, estimated from 792 cases)
or non-Hispanic blacks (11.2%, estimated from 186
cases).
Allele and genotype frequency
The e2 allele was the rarest allele for each ethnicity, with
population frequencies estimated at 3.4%, 9.7% and
7.8% in Mexican Americans, non-Hispanic blacks and
non-Hispanic whites, respectively (table 2). Frequency of
the e4 allele was 10.8% among Mexican Americans, com-
pared to 15% in whites and 22% in non-Hispanic blacks.
The most common genotypes e2/e3, e3/e3, and e3/e4
made up 95% of the non-Hispanic white genotypes, 89%
of non-Hispanic black genotypes and 97% of Mexican-
American genotypes. The e2/e2 genotype was rare in all
groups (1% in non-Hispanic whites and blacks and 0.1%
Table 1: Estimated weighted population characteristics of 5,583 NHANES III Genetic Study (1991-1994) participants by ethnicity*
Non-Hispanic white Non-Hispanic black Mexican American
Mean/% SE Mean/% SE Mean/% SE
Number of subjects (n) 2,328 1,599 1,656
Age (y) 46.2 0.9 41.8 0.8 37.4 0.6
Body mass index (kg/m2) 26.6 0.2 28.2 0.3 27.8 0.9
Male (%) 48.1 1.0 44.2 1.3 52.1 1.0
Diabetes (%) 6.8 0.6 9.4 0.8 8.4 0.9
Hypertension (%) 29.4 1.9 38.2 1.7 22.7 1.4
High blood cholesterol (%) 30.4 1.0 20.8 0.9 16.6 1.0
Cardiovascular disease (%) 8.9 0.9 10.8 0.8 7.5 0.7
Obesity (%) 23.1 1.2 32.8 1.2 29.0 0.8
High school degree (%) 82.9 1.2 68.3 2.4 55.5 2.7
Serum creatinine (mg/dL) 0.86 0.01 0.93 0.01 0.78 0.00
Never smoked (%) 74.3 1.9 68.6 1.0 78.6 1.2
Cystatin C (mg/dL) 0.98 0.02 0.94 0.03 0.87 0.02
Albumin to creatinine ratio  18.88 1.74 37.06 4.90 53.15 14.61
Triglycerides (mg/dL) 148.98 2.94 117.71 1.74 161.63 4.03
High density lipoprotein cholesterol (mg/dL) 49.73 0.63 54.53 0.54 47.49 0.50
C-reactive protein (mg/L) 0.40 0.02 0.52 0.02 0.46 0.03
Estimated glomerular filtration rate (ml/min/1.73 m2) 88.2 0.8 101.4 0.9 103.7 0.7
Low-glomerular filtration rate cases (GFR <75) (%) 22.8 1.5 11.2 1.2 6.4 0.8
* All between ethnicity group comparisons are statistically significant, p < 0.05.
Table 2: APOE allele and genotype counts and population frequencies* of NHANES III Genetic Study (1991-1994) by ethnicity
Non-Hispanic white Non-Hispanic black Mexican American
Allele/Genotype count population frequency count population frequency count Population frequency
e2 407 0.08 326 0.10 115 0.03
e3 3,557 0.77 2,186 0.68 2,854 0.86
e4 692 0.15 686 0.22 343 0.11
e2/e2 17 0.01 9 0.01 1 0.001
e2/e3 315 0.13 237 0.14 100 0.06
e 2 / e 4 5 80 . 0 27 10 . 0 51 30 . 0 1
e3/e3 1,354 0.58 745 0.46 1,238 0.74
e3/e4 534 0.24 459 0.29 278 0.17
e 4 / e 4 5 00 . 0 27 80 . 0 52 60 . 0 2
* The count is based on samples in NHANES III; the population frequency is estimated from the number of samples using sampling weights from 
NHANES IIIBMC Medical Genetics 2009, 10:108 http://www.biomedcentral.com/1471-2350/10/108
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in Mexican Americans) and was found in only one Mexi-
can American participant.
Univariate association between APOE variants with low-
GFR cases by MDRD equation in case-control analysis
Each e4 allele was inversely associated with low-GFR cases
in non-Hispanic whites (OR: 0.76, 95%CI: 0.60, 0.97) as
shown in table 3. In non-Hispanic blacks, e4 was seen
with slightly lower odds of low-GFR (OR: 0.95, 95%CI:
0.69, 1.32), but the association was not significant. There
was no association of the e2 allele and low-GFR in any of
the three ethnicities. Associations between APOE varia-
tions and low-GFR in Mexican Americans were not con-
sistent with the findings among whites and blacks in
univariate or multivariate analyses.
Similar results were obtained in univariate APOE sum-
mary score analysis and prevalence of low-GFR (table 3).
In non-Hispanic whites, each increasing APOE summary
score point (representing greater number of e2 alleles) sig-
nificantly increased the odds of low-GFR by 21% (OR:
1.21, 95%CI: 1.01, 1.45), therefore individuals with the
e2/e2 genotype have a 21% increased odds of low-GFR
compared to those with the e2/e3 genotype. We observed
a similar trend of increasing summary score with low-GFR
cases in non-Hispanic blacks, but the association was not
significant (table 3). No consistent association of APOE
score and low-GFR cases was seen among Mexican Amer-
icans.
Power calculations were performed for association
between the e4 allele, the e2 allele, and APOE score with
low-GFR cases by ethnicity.  was set at 0.05 for all calcu-
lations. In non-Hispanic whites, with a fixed sample size
of 2,328 and observed prevalence of low-GFR cases of
22.8%, and an e4 allele frequency of 0.15, we have 80%
power to detect an odds ratio of 0.76. Using the same sam-
ple size and disease prevalence parameters, with an e2
allele frequency of 0.08, we have 31% power to detect an
odds ratio of 1.20. Using the same sample size and disease
Table 3: Odds Ratios of low-GFR cases (GFR < 75 ml/min/1.73 m2) by the MDRD equation and CKD-EPI formula associated with the 
e2 allele, e4 allele, and APOE score in NHANES III Genetic Study (1991-1994) participants by ethnicity
APOE e2 APOE e4 APOE score
OR 95%CI OR 95%CI OR 95%CI
Non-Hispanic white
MDRD equation
Crude 1.08 0.81, 1.45 0.76* 0.60, 0.97 1.21* 1.01, 1.45
Minimally adjusted 0.96 0.66, 1.39 0.82 0.60, 1.14 1.10 0.88, 1.38
Final 0.99 0.69, 1.44 0.83 0.60, 1.15 1.11 0.87, 1.42
CKD-EPI formula
Crude 1.21 0.82, 1.79 0.72* 0.59, 0.88 1.31* 1.06, 1.60
Minimally adjusted 1.10 0.61, 1.99 0.82 0.65, 1.05 1.16 0.90, 1.50
Final 1.12 0.59, 2.14 0.77 0.58, 1.02 1.22 0.92, 1.62
Non-Hispanic black
MDRD equation
Crude 1.45 0.91, 2.33 0.95 0.69, 1.32 1.19 0.96, 1.49
Minimally adjusted 1.50 0.91, 2.50 1.01 0.72, 1.42 1.16 0.92, 1.46
Final 1.37 0.79, 2.38 1.07 0.75, 1.53 1.08 0.87, 1.36
CKD-EPI formula
Crude 1.29 0.69, 2.41 0.88 0.67, 1.18 1.19 0.89, 1.59
Minimally adjusted 1.42 0.73, 2.76 0.92 0.70, 1.21 1.20 0.86, 1.68
Final 1.26 0.63, 2.52 0.94 0.68, 1.29 1.13 0.83, 1.57
Mexican American
MDRD equation
Crude 0.71 0.34, 1.48 1.12 0.69, 1.79 0.85 0.57, 1.28
Minimally adjusted 0.77 0.34, 1.72 1.13 0.71, 1.82 0.85 0.57, 1.28
Final 0.77 0.34, 1.81 1.14 0.71, 1.86 0.85 0.57, 1.27
CKD-EPI formula
Crude 0.90 0.45, 1.80 0.90 0.48, 1.66 1.05 0.66, 1.67
Minimally adjusted 0.97 0.44, 2.12 0.92 0.43, 1.99 1.05 0.62, 1.79
Final 0.95 0.37, 2.42 0.85 0.39, 1.85 1.10 0.66, 1.84
Crude model adjusted for e2 and e4 allele
Minimally adjusted model includes the crude model plus age and sex
Final model includes the minimally adjusted model plus education, ever/never smoking, CRP, triglycerides, HDL cholesterol, TSH, obesity, diabetes, 
hypertension and presence of albuminuria
*p < 0.05BMC Medical Genetics 2009, 10:108 http://www.biomedcentral.com/1471-2350/10/108
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prevalence parameters, with the observed APOE score dis-
tribution for non-Hispanic whites from (table 2), we have
71% power to detect an odds ratio of 1.20.
In non-Hispanic blacks, with a fixed sample size of 1,599,
observed prevalence of low-GFR cases of 11.2%, and an e4
allele frequency of 0.22, we have 53% power to detect an
odds ratio of 0.76. Using the same sample size and disease
prevalence parameters, with an e2 allele frequency of
0.11, we have 17% power to detect an odds ratio of 1.20.
Using the same sample size and disease prevalence
parameters, with the observed APOE score distribution for
non-Hispanic blacks from (table 2), we have 44% power
to detect an odds ratio of 1.20.
In Mexican Americans, with a fixed sample size of 1,656,
observed prevalence of low-GFR cases of 6.4%, and an e4
allele frequency of 0.11, we have 22% power to detect an
odds ratio of 0.76. Using the same sample size and disease
prevalence parameters, with an e2 allele frequency of
0.03, we have 7% power to detect an odds ratio of 1.20.
Using the same sample size and disease prevalence
parameters, with the observed APOE score distribution for
Mexican Americans from (table 2), we have 18% power to
detect an odds ratio of 1.20.
Multivariate association between APOE variants with 
low-GFR cases by MDRD equation in case-control analysis
In non-Hispanic whites, adjusting for age and sex revealed
a suggestive association between the e4 allele and
decreased prevalence of low-GFR in non-Hispanic whites
(table 3). This adjustment, however, attenuated the asso-
ciation of the e4 allele and low-GFR and diminished sig-
nificance. The final multivariate models included APOE
variants, age, sex, education, ever/never smoking, HDL
cholesterol, CRP, triglycerides, TSH, diabetes, hyperten-
sion, obesity and albuminuria. In our final model, the
APOE e4 allele tended to associate with lower prevalence
of low-GFR cases in Non-Hispanic whites. No significant
associations were observed with the e2 allele, although
the odds ratios were consistently greater than the null in
non-Hispanic blacks.
Although score analysis of our final multivariate model
supported findings from the additive genetic models, i.e.
per point increase in APOE summary score tended to asso-
ciated with low-GFR cases in non-Hispanic whites (OR:
1.11, 95%CI: 0.87, 1.42) and blacks (OR: 1.08, 95%CI:
0.87, 1.36), these estimates did not reach statistical signif-
icance.
Association between APOE variants with low-GFR cases 
by MDRD equation in case-control analysis adjusting for 
albuminuria
To examine the association of APOE alleles and low-GFR
cases independent of kidney damage, we adjusted for
albuminuria (ACR >30 ug/mg) in our univariate models.
Table 4 shows models adjusted for albuminuria by ethnic-
ity. Adjustment for albuminuria in the non-Hispanic
whites showed that APOE e4 allele tended to associate
with low-GFR cases (OR: 0.77, 95%CI: 0.59, 1.01, p =
0.06). Moreover, the APOE score summary was also sig-
nificantly associated with low-GFR cases after adjusting
for albuminuria (OR: 1.21, 95%CI: 1.00, 1.46). Consist-
ent positive associations of APOE  score summary and
low-GFR cases were seen in non-Hispanic blacks after
adjustment for albuminuria. However, none of the associ-
ations attained statistical significance (table 4).
Association of APOE and continuous GFR by MDRD 
equation
In non-Hispanic whites, analysis of continuous GFR esti-
mated by the MDRD equation, each e4 allele was associ-
ated with a 2.57 ml/min/1.73 m2  higher GFR level
(95%CI: 0.005, 5.14 ml/min/1.73 m2). The e2 allele was
not associated with GFR level (: 1.23 ml/min/1.73 m2,
95%CI: -1.90, 4.38) in whites. In non-Hispanic blacks,
the e2 allele associated with a 3.73 ml/min/1.73 m2 lower
GFR level (95%CI: -6.61, -0.84 ml/min/1.73 m2). The e4
allele tended towards association with lower GFR level in
blacks (: -1.63 ml/min/1.73 m2, 95%CI: -4.38, 0.18), but
was not significant.
Table 4: Odds Ratios of GFR < 75 ml/min/1.73 m2 by the MDRD equation associated with the e2 allele, the e4 allele, and APOE score 
adjusted for albuminuria in NHANES III Genetic Study (1991-1994) participants by ethnicity
APOE e2 APOE e4 APOE score
OR 95%CI OR 95%CI OR 95%CI
Non-Hispanic whites 1.10 0.81, 1.48 0.77 0.59, 1.01 1.21* 1.00, 1.46
Non-Hispanic blacks 1.34 0.80, 2.25 0.90 0.65, 1.24 1.19 0.995, 1.44
Mexican Americans 0.77 0.36, 1.68 1.14 0.72, 1.80 0.85 0.56, 1.31
Models adjusted for the e2 and e4 allele, and albuminuria (albumin-creatinine ratio >30 ug/mg)
*p < 0.05BMC Medical Genetics 2009, 10:108 http://www.biomedcentral.com/1471-2350/10/108
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Association of APOE and low GFR by CKD-EPI Equation 
and continuous GFR by CKD-EPI equation
To confirm that the association between APOE and low
GFR was not specific to the MDRD equation, we also esti-
mated GFR using the newly developed CKD-EPI equation
[49]. The CKD-EPI formula estimated lower prevalence of
low-GFR cases compared to the MDRD formula (4.1% in
non-Hispanic whites, 16.0% in non-Hispanic blacks and
11.2% in Mexican Americans). Despite different preva-
lence estimates, similar associations were observed in
analysis of APOE  polymorphisms and APOE  score
method with low-GFR cases in non-Hispanic whites and
blacks in univariate and multivariate analyses (Table 3).
Continuous analysis of GFR by CKD-EPI equation
revealed similar associations as continuous analyses of
GFR by MDRD equation in both non-Hispanic whites and
non-Hispanic blacks (data not shown).
Discussion
Following on previous work, we replicated the inverse
association between APOE e4 allele and low-GFR cases in
non-Hispanic whites. The APOE e4 allele was significantly
associated with decreased prevalence of low-GFR cases in
non-Hispanic whites, and higher levels of continuous
GFR. Individuals with a copy of the e4 allele had 24%
lower odds of a GFR less than 75 ml/min/1.73 m2, and,
on average, a 2.57 ml/min/1.73 m2 higher GFR. The e2
allele did not associate with low-GFR cases (or lower lev-
els of continuous GFR). We observed a weak, but signifi-
cant, association between increasing APOE  summary
score points (greater number of e2 alleles) and higher
prevalence of low-GFR cases. Additionally, this observed
association between APOE summary score and low-GFR
cases was independent of a kidney damage mechanism, as
seen in the model adjusting for albuminuria. We had pre-
viously implemented the APOE summary score to detect
an association of APOE variation with kidney function
[28], and obtained similar effects after full adjustment for
confounders. In light of previously published studies
demonstrating positive relationship between APOE vari-
ants and CKD, the suggestive evidence from this study,
and considering the wide age range and the non-clinical
nature of NHANES III, we believe our results support and
replicate the association between genetic variations of
APOE and low-GFR cases in non-Hispanic whites.
While we did not observe a significant association of
APOE  polymorphisms with prevalence of low-GFR in
non-Hispanic blacks due to low power (see Univariate
Association under Results) we did observe an association
between the e2 polymorphism and lower levels of contin-
uous GFR. Additionally, the odds ratios for blacks for e2,
e4 and the APOE score method from our study are consist-
ent with the hazard ratios of APOE and progression of
CKD estimated from African Americans in the Atheroscle-
rosis Risk in Communities (ARIC) study [28]. No associa-
tion was detected between APOE  polymorphism and
prevalence of low-GFR or continuously measured GFR in
Mexican Americans. The APOE e2 and e4 allele frequen-
cies were very low in Mexican Americans and our analysis
did not have enough power to detect an association (see
Univariate Association under  Results), even if one
existed.
This is the first study of APOE and estimated kidney func-
tion in Mexican Americans and establishes population-
based allele frequencies in a nationally representative
population of Mexican Americans. APOE  variation is
uncommon in Mexican Americans. The frequency of the
e2 allele is 3.5% and the e4 allele is 11% in Mexican
Americans from NHANES III. These estimates are consist-
ent with results from smaller regional cohorts, e2: 2.4 -
4.8% and e4: 6.9 - 9.9% [50-52]. The combination of low
allele frequency and low prevalence of estimated GFR <75
ml/min/1.73 m2 (6.4%) in this population resulted in an
underpowered analysis to detect the significant associa-
tion observed in non-Hispanic whites. Moreover, the lack
of observed association in this population could be due to
the need for a validated equation to estimate kidney func-
tion in Mexican Americans, but could also indicate APOE
variants are not associated with or have minimal effect on
kidney function in this population.
The odds ratios obtained from analysis of APOE summary
score and low-GFR cases were similar to the estimates pre-
viously observed in ARIC - an increase in the number of
e2 alleles was observed with an increased prevalence of
low-GFR cases, or alternately, the decrease in the number
of e2 alleles was associated with lower prevalence of low-
GFR cases [28]. Our adjusted estimates were not signifi-
cant, possibly due to the smaller sample size of NHANES
III genetic study compared to ARIC. Nevertheless, the
direction of association and magnitude of the association
are consistent between the two studies.
The inverse association between the e4 allele and preva-
lence of low-GFR cases (GFR<75 ml/min/1.73 m2) is an
important finding in determining whether APOE varia-
tion is a risk factor for kidney disease. Studies of end-stage
renal disease (ESRD) patients show lower prevalence of
the e4 allele in ESRD than the general population [53].
The e4 allele and e3/e4 - e4/e4 genotypes are found in
lower frequency in patients with glomerular nephropathy
[21]. The e4 allele was found to be protective for onset
and progression of diabetic nephropathy in type 2 diabe-
tes [20,54].
Greater prevalence of the e2 allele has been observed in
ESRD patients compared to the general population [53].
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progression of diabetic nephropathy in type 2 diabetes
[13]. The e2 allele was also found to be associated with
development of diabetic nephropathy in type 1 diabetics
[14]. Several studies have produced null results from
investigations of ApoE and renal disease, but were gener-
ally underpowered [20,55]. A substantial body of research
has consistently demonstrated the e2 allele is associated
with increased risk of renal dysfunction and the e4 allele
is inversely associated with risk of renal disease.
In order to assess whether this relationship is causal, addi-
tional investigations into the molecular pathways of dif-
ferent forms of ApoE on the pathophysiology of CKD and
kidney function need to be carried out. The pathway by
which ApoE acts on the kidney has yet to be precisely
delineated. However, dysfunctional kidney repair func-
tions (ineffective remodeling and mesangial cell prolifer-
ation) have been implicated in previous studies [24].
Change in membrane permeability also may lead to
derangement of kidney function.
Differences in APOE genotype frequencies may account
for some of the differences in low-GFR prevalence across
ethnic subpopulations. In non-Hispanic blacks, we
expected higher e2 allele frequencies due to an increased
prevalence of CKD, and we expected lower frequencies of
the e2 allele in Mexican-Americans due to lower preva-
lence of CKD in this population. We have identified a very
low prevalence of the e2 allele and thus low frequencies of
the e2/e2, e2/e3 and e2/e4 genotypes in a population
based sample of Mexican-Americans, consistent with pre-
viously published results [50,51]. We cannot make further
inferences of the effect of e2 on estimated kidney function
beyond the consistent, yet non-significant association
with higher prevalence of low-GFR.
We chose to use GFR<75 ml/min/1.73 m2 to define cases
and not the National Kidney Foundation's (NKF) stand-
ard definition for stage 3 CKD (GFR<60 ml/min/1.73 m2)
since using the NKF definition resulted in severely under-
powered analyses (see Univariate association under
Results). Comparison of results from univariate analyses
using a case definition of GFR<60 ml/min/1.73 m2
showed similar association of case status with APOE2
(OR: 1.07, 95%CI: 0.61, 1.87), APOE4 (OR: 0.82, 95%CI:
0.58-1.17) and APOE score (OR: 1.15, 95%CI: 0.84-1.56)
as our current results with case definition of GFR<75 ml/
min/1.73 m2, but were not statistically significant. Addi-
tionally, similar risk factors have been associated with
both cases defined by GFR<75 ml/min/1.73 m2 and cases
defined by GFR<60 ml/min/1.73 m2 [43].
This study is large and representative of the general U.S.
population, and findings in this study are consistent with
previous results. However there are several limitations.
First, CKD is clinically defined by altered kidney function
or structure for a period of three months or more. The sin-
gle serum creatinine measurement used in our study to
estimate GFR may have lead to misclassification of disease
status and decreased power. Second, CKD was defined
based on estimated GFR from the MDRD equation and
the CKD-EPI formula rather than the gold standard meth-
ods of direct measurement of glomerular function using
inulin clearance, iothalamate clearance and creatinine
clearance. Third, serum creatinine measures are higher in
individuals with large amounts of muscle mass [56], in
addition to individuals with impaired kidney function.
Therefore, the low GFR estimates generated for those with
high muscle mass could indicate worse kidney function
than in reality. This misclassification could lead to an
attenuation of the association between APOE and CKD.
Fourth, neither the MDRD equation nor the CKD-EPI for-
mula has been validated in Mexican Americans. Lastly,
there is the possibility the relationship between APOE var-
iation and CKD is due to survivor bias; we observed a
slight decline in e4 allele frequency with increasing age in
all three ethnic groups. However, analyses stratified by age
groups revealed similar associations to unstratified analy-
sis (data not shown).
One of the main strengths of the present study was the
large, nationally representative, population-based sample
of non-Hispanic whites, non-Hispanic blacks and Mexi-
can Americans. Previous epidemiologic studies have
shown risk of CKD associated with APOE variants mostly
in clinic-based and international samples [13,14,19-
21,28,32,53,54]. Our generalizable results provide evi-
dence to support the effects of APOE variants on CKD. In
addition, reverse causality - often a problem with cross-
sectional studies - is not an issue here since APOE gene
variants should precede all manifestations of CKD, and
therefore cannot be affected by the presence of CKD.
Conclusion
Observational epidemiology studies have supplied popu-
lation-based evidence of the effect of APOE variations on
prevalence and progression of kidney disease [28,32]. The
e4 allele is consistently associated with decreased risk of
CKD/low-GFR in whites. But, we cannot rule out a sur-
vival bias as a source of confounding for the association
between the e4 allele and higher estimated kidney func-
tion. Replication of these findings in a large population of
whites is necessary, as are future efforts in large multieth-
nic populations to understand the possible impact of
APOE  polymorphism in the population. In addition,
research of CKD and ApoE should be directed towards the
elucidation of the molecular biology of kidney disease
and mechanisms through which different forms of APOE
may play a modulating role. These mechanisms would
ideally include the effect of maintenance and repair ofBMC Medical Genetics 2009, 10:108 http://www.biomedcentral.com/1471-2350/10/108
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kidney structures on the permeability of the glomerular
membrane. Additionally, physiology studies would aim
to determine what role age and survival play in the effect
of APOE on kidney unction, as well as validating equa-
tions of estimated kidney function in ethnic minorities.
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